Study ID: TV48574-AS-20031 | 2020-001927-15

Study Title

A Study to Test if TEV-48574 is Effective in Relieving Asthma

Teva Identifier

TV48574-AS-20031 | 2020-001927-15

ClinicalTrials.gov Identifier

NCT04545385

Study Status

Terminated

Trial Condition(s)

Asthma

Interventions

Drug: TEV-48574 | Drug: Placebo

EudractCT Number

2020-001927-15

Study Description

The primary objective of the study is to evaluate the effect of TEV-48574 compared with placebo on loss of asthma control (LoAC) in adult patients with T2-low and non-T2 severe asthma uncontrolled on inhaled corticosteroids plus long-acting beta-agonists (ICS+LABA).

The secondary efficacy objective is to evaluate the effect of TEV-48574 compared with placebo on a range of clinical measures of asthma control.

The duration of patient participation in the study is planned to be up to approximately 30 weeks.

ClinicalTrials.gov study records with inclusion and exclusion criteria

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years and older

Trial Duration

August 25, 2020 - January 17, 2022

Phase

Phase 2

Additional info

Study Type

Interventional